FindTrial
Sign In

Variability of dynamic contrast-enhanced MRI in the pituitary adenoma: Prospective comparison between gadobutrol and meglumine gadoterate usage

Variability of dynamic contrast-enhanced MRI in the pituitary adenoma: Prospective comparison between gadobutrol and meglumine gadoterate usage

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006668
Enrollment
74
Registered
2021-10-15
Start date
2021-10-20
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Seoul National University Bundang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults who are planned to undergo pituitary MRI including DCE-MRI for the suspicion of the pituitary tumor and agree to be included in this prospective study

Exclusion criteria

Exclusion criteria: -Exclusion criteria: Under age 19 years old, pregant woman, those who do not agree to be included in this study, those who have history of side effect for the gadolinium-based MRI contrast agent including allergic reaction, those who have severe kidney or heart problem, those who have intractable hypokalemia, those who cannot be injected with gadolinium-based MRI contrast-agent from various reasons

Design outcomes

Primary

MeasureTime frame
volume transfer (Ktrans, Kep), extracellular space volume (Ve), plasma volume (Vp), and area-under-the-curve (AUC)—

Secondary

MeasureTime frame
diagnostic performance for the pituitary adenoma—

Countries

Korea, Republic of

Contacts

Public ContactYun Jung Bae

Seoul National University Bundang Hospital

bae729@gmail.com+82-31-787-7635

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026